JPMorgan raises CG Oncology stock price target on trial data

JPMorgan raised its price target for CG Oncology (CGON) to $113 from $96, citing positive trial data and regulatory updates. The stock, currently at $84.78, has surged over 104% year-to-date. JPMorgan increased its success probability for Creto in bladder cancer treatments, projecting $1.2B and $1.0B in U.S. peak sales by 2037 for different settings. RBC Capital downgraded CGON to Sector Perform but raised its target to $97.

Original reporting
Published Nov 17, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$CGON
Bullish
medium confidence
Mentioned
$CGON
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CGONBullishMed
01

Why it matters

The key trading takeaway is the model update: JPMorgan increased probability of success in specific settings and raised risk-adjusted peak sales assumptions, resulting in a higher $113 target while keeping an Overweight rating.

02

Market read

A sell-side target increase with explicit trial-linked DCF inputs can drive near-term trading flows, but the magnitude of prior run-up and competing analyst views may limit follow-through.

03

What to watch

RBC’s concurrent downgrade to Sector Perform suggests the market may be split on how much the new read-through should de-risk the program, increasing volatility around further trial/regulatory milestones.

Relevance 7/10Novelty 5/10Timing: today, as a new analyst price-target update can move positioning immediately

Background

CG Oncology is being evaluated on creto trial readouts, with JPMorgan updating its DCF assumptions after an intermediate-risk readout and a regulatory update.

Company-level read

Ticker impact

$CGONBullishMedium confidence
Context

JPMorgan raised CG Oncology’s price target to $113 from $96 after an intermediate-risk readout and a regulatory update tied to its creto trial.

Expected impact

Likely upward bias as traders price in improved trial/regulatory read-through, though upside may be capped if expectations are already elevated.

Evidence & confidence

The article is a fresh sell-side target change with explicit model inputs (probability of success, risk-adjusted peak sales) and a new $113 target, which can drive incremental flows. However, it is still analyst-driven rather than a new primary clinical/regulatory disclosure.

Market effects

Reinforces positive sentiment for bladder cancer oncology names tied to intermediate-risk read-throughs, potentially lifting peer sentiment even without new peer-specific catalysts.

Limited direct regional impact; primarily a US biotech sentiment/positioning signal.

Modest global relevance as it is a single-company analyst model update rather than a cross-market regulatory or trial headline.

Counterpoint

The stock has already surged over 104% YTD, so the incremental target raise may be less impactful than the market’s prior expectations; valuation concerns could dominate.

Key entities

  • CG Oncology

    NASDAQ-listed biotech whose creto trial read-through prompted JPMorgan to raise its price target.

  • JPMorgan

    Raised CG Oncology’s price target to $113 from $96 and maintained Overweight.

  • RBC Capital

    Downgraded CG Oncology to Sector Perform from Outperform despite raising its target to $97.

  • PIVOT-6 trial

    Intermediate-risk readout referenced as part of the rationale for JPMorgan’s updated assumptions.

Related articles

$CGONMed

CG Oncology Stock Falls 7% as RBC Downgrade Cools Rally After Bladder Cancer Drug Cuts Recurrence Risk by 68%

CG Oncology Inc. shares fell 7.53% on Tuesday, after a 14% rise on Monday following positive trial results for its bladder cancer treatment. RBC downgraded the stock to Sector Perform, citing regulatory path, despite raising its price target to $97. The Phase 3 trial showed a 68% reduction in cancer recurrence risk. Other analysts raised price targets, with JPMorgan at $113 and Truist at $100.

$CGONMed

Truist raises CG Oncology stock price target on trial results

Truist Securities raised its price target for CG Oncology (CGON) to $100 from $85, citing positive PIVOT-006 trial results. The stock is up 16.7% over the past week. Full data will be presented in December 2026, with FDA submissions expected in 2027. Analysts have revised earnings estimates upward, highlighting a multi-billion-dollar market opportunity.

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.